兔骨髓间充质干细胞Ⅱ型胶原表达的实验研究

目的探讨兔骨髓间充质干细胞表达Ⅱ型胶原的实验研究方法。方法利用β1转化生长因子腺病毒表达载体（Ad—TGFβ1）转染兔骨髓间充质干细胞（MSCs），观察转染后的Ⅱ型胶原表达。结果细胞转染后Ⅱ型胶原在免疫印记和免疫组化检测下均呈强阳性表达。结论Ad—TGFβI转染兔骨髓MSCs可使其细胞内Ⅱ型胶原表达阳性。     

Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention.

This study evaluated the safety and efficacy of batroxobin in treating hyperfibrinogenemia for secondary stroke prevention. Patients with ischemic stroke or transient ischemic attack (TIA) were measured for plasma fibrinogen levels. Selected participants had concomitant hyperfibrinogenemia (plasma fibrinogen > or = 3.0 g/l). Patients enrolled between 1 July 2003 and 31 December 2004 were treated with batroxobin; patients enrolled between 1 January 2002 and 30 June 2003 were treated without batroxobin. Batroxobin was administered intermittently via intravenous injection at 3-monthly intervals. Patients in both groups were followed for 1 year. Any cerebrovascular events and suspected adverse events were recorded. In total, 112 ischemic stroke/TIA patients with concomitant hyperfibrinogenemia were enrolled, 52 being treated with batroxobin and 60 without batroxobin. Six patients (11.5%) with batroxobin and 16 patients (26.7%) without batroxobin had recurrent cerebral ischemic events during follow-up. Stroke/TIA recurrence in patients without batroxobin was higher than that in patients with batroxobin (P < 0.05). Two patients with batroxobin and two patients without batroxobin developed hemorrhagic stroke during follow-up. There were five deaths (9.6%) in the batroxobin group, and seven deaths (11.7%) in the nonbatroxobin group during follow-up (P > 0.05). Intermittent intravenous injection of batroxobin can efficiently reduce the risk for stroke/TIA recurrence in patients with concomitant hyperfibrinogenemia.     

三氧化二砷纳米微粒对抑制兔血管平滑肌细胞增殖作用的实验研究

目的 了解纳米微粒与普通剂型的三氧化二砷（As2O3）对抑制体外培养的兔血管平滑肌细胞（VSMC）增殖作用的差别。方法 对照组为不加药物的细胞，实验组为3μmol／L纳米微粒和普通剂型的As2O3，干预体外培养的兔VSMC细胞72h，进行四唑氮盐（MTT）染色测定细胞吸光度（A）值。用流式细胞仪检测细胞凋亡情况，提取细胞DNA，进行凝胶电泳分析，将3组的结果进行比较。结果 3μmol／L纳米剂型的As2O3，干预细胞，细胞数量随作用时间的延长逐渐减少，细胞生长明显受抑制，而普通剂型干预细胞，生长受抑制程度较纳米剂型弱。24h时，对照组、3μmol／L普通剂型组与纳米组，A值分别为0．68±0．10、0．58±0．12、0．33±0．12，48h时分别为0．79±0．11、0．48±0．14、0．28±0．11，72h时分别为0．96±0．13、0．34±0．15、0．20士0．06，差异均有统计学意义（Ⅳ值分别为10．934、15．039、15．539，P值均〈0．01）。流式细胞仪检测，纳米剂型As2O3、普通剂型As2O3干预及对照组的细胞干预48h，细胞增殖率分别为44．97％、58．54％、74．02％，早期凋亡率分别为16．89％、11．27％、11．20％，晚期凋亡率分别为26．56％、23．60％、12．46％，坏死细胞分别为11．58％、6．59％、2．32％。DNA电泳，As2O3干预细胞，可见凋亡梯形条带，部分细胞坏死，呈模糊的无间隔片状条带。纳米剂型药物作用的细胞DNA条带，梯形条带更多、更模糊。结论 As2O3，可以抑制体外培养的VSMC增殖，且纳米剂型As2O3较普通剂型的As2O3，对细胞抑制作用更强。     

岛状皮瓣修复瘢痕性睑外翻

目的探讨眼轮匝肌蒂颞部岛状皮瓣与颞浅动脉蒂反流轴型耳后岛状皮瓣在修复瘢痕性睑外翻中的应用,提高睑外翻矫正后所致皮肤缺损的美学修复效果。方法自1998年2月以来,对18例瘢痕性睑外翻,采用眼轮匝肌蒂颞部岛状皮瓣旋转180°移位修复13例,皮瓣最大面积2.7cm×3.6cm;采用颞浅动脉蒂反流轴型耳后岛状皮瓣经面部皮下隧道转移修复5例,皮瓣最大面积3.1cm×5.4cm。结果1例反流轴型耳后岛状皮瓣术后出现静脉回流障碍,经对症处理后仅皮瓣远端部分表皮坏死,Ⅱ期植皮后治愈,其余17例皮瓣完全成活。随访6个月,睑外翻矫正,皮瓣颜色、质地与眼周皮肤相近,供区瘢痕不明显。结论根据睑外翻程度,可制备颞部岛状皮瓣或耳后岛状皮瓣转移。前者适用于修复较小面积的皮肤缺损,后者适用于修复较大面积的皮肤缺损。     

灵芝菌合剂中灵芝多糖含量的测定

目的：探讨灵芝菌合剂中灵芝多糖含量的检测方法。方法：采用分光光度法，以无水葡萄糖为对照品，检测波长为490nm。结果：此方法在0～120μg范围内线性关系良好，灵芝多糖的平均回收率为99．09%。RSB为1．14％。结论：本法简便快捷，准确度高，重现性好，可作为本制剂的质控方法。     

针刺对肾血管性高血压大鼠的降压效应

目的　探讨针刺对肾血管性高血压大鼠的降压作用及其神经 -内分泌调节机制。方法　采用二肾一夹法制备高血压大鼠模型 ,测定实验各组大鼠血浆内皮素 (ET)、一氧化氮 (NO)含量和心率变异性 (HRV)的动态变化。结果　与模型组相比 ,针刺组血压 (BL 2 3:19.1± 1.1k Pa,ST36:18.1± 2 .5 k Pa)及 ET水平明显下降 (P<0 .0 1) ,其中针刺肾俞组血浆 ET水平 (91.3± 9.45 pg/ ml)较足三里组 (10 8.48± 13.0 6pg/ ml)下降更明显 (P<0 .0 5 ) ;针刺治疗组血浆 NO水平 (BL 2 3:5 0 .3±12 .7μmol/ ml,ST 36:49.71± 8.49μm ol/ m l)显著升高 (P<0 .0 5 )。足三里组针刺后 L F/ HF比值与模型组无明显差异 ,而肾俞组 L F/ HF值 (0 .5 7± 0 .13)明显低于模型组及足三里组 (0 .86± 0 .2 5 )。结论　针刺能降低肾血管性高血压模型大鼠动脉血压 ,肾俞与足三里两穴无明显差异 ,其作用机制可能与自主神经系统、NO及 ET参与的神经内分泌调节作用相关。     

解析南非医疗『公私合营』机制

南非在建立和发展公平、高效、高质量的医疗保障体系的过程中,为公立医疗机构和私立医疗机构之间开展建设性的合作提供了相当大的空间。当决定是否应该在医疗体系中追求新的公私互动或公私合营机制之前,有必要对现有这种机制的功过是非、全民医疗体系的目标和已经取得的成绩进行认真评估。     

神经病学临床见习教学的思考

本文从多方面介绍了神经病学临床见习的教学方法,认为临床见习的重点是理论联系实际及学生临床思维能力的培养,促进医学生向医生的转变。     

Food-dependent exercise-induced anaphylaxis in childhood

The clinical syndrome of food-dependent exercise-induced anaphylaxis (FDEIA) is typified by the onset of anaphylaxis during (or soon after) exercise which was preceded by the ingestion of the causal food allergen/s. In FDEIA, both the food allergen/s and exercise are independently tolerated. FDEIA is an uncommon allergic condition in childhood, but nonetheless is an important differential diagnosis to be considered when faced by a child who has experienced exercise-associated anaphylaxis. The diagnosis of FDEIA is heavily dependent on the clinical history. Allergy tests may need to be performed to a broad panel of food and food additives. Modified exercise challenges (performed with and without prior ingestion of food) are frequently required as allergy test results frequently return low-positive results. A diagnosis of FDEIA facilitates the safe independent return to exercise and reintroduction of foods for patients who otherwise may unnecessarily avoid exercise and/or restrict their diet. The natural history of FDEIA is unknown; however, a safe return is usually achieved when the ingestion of the causal food allergen/s and exercise are separated.     

脐血铅水平与妊娠结局及影响因素的关系

目的 :了解本地区脐血铅水平现状及其妊娠结局与妊娠并发症 ,新生儿体格发育及神经行为发育的关系 ,并探讨脐血铅与环境因素的关系。方法 :采用 HB2 10 0原子吸收光谱仪用原子吸收法测定 178例经剖宫分娩的新生儿脐带血水平 ,同时观察孕妇妊娠与分娩期有无合并症与并发症 ,并于新生儿出生后即刻测量体重、身长 ,2 4 h内测量头围、胸围和腹围 ,采用神经行为发育量表 ,对出生后 4 2 d的 5 0例婴儿进行神经行为发育评分。同时对产妇家庭环境等相关因素进行问卷调查。结果 :178例脐血铅最高值 12 2 μg/ L,最低值 1μg/ L,中位数 36 μg/ L,脐血铅≥ 10 0 μg/ L 者 6例 ,占3.33%。脐血铅水平与妊娠并发症无明显相关性 ,与新生儿体格发育及神经行为发育评分无明显相关性。新生儿血铅水平与环境因素 (家庭住址、居室新旧、家庭经济情况、职业等 )差异有显著性 ,P<0 .0 5。结论 :本组脐血铅水平与孕期并发症及新生儿体格发育及神经行为发育评分无明显关系。脐血铅水平与环境因素有关。